**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 91461

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Predicting short-term thromboembolic risk following Roux-en-Y gastric bypass using supervised machine learning**

Ali H *et al*. Predicting thromboembolic risk following RYGB

Hassam Ali, Faisal Inayat, Vishali Moond, Ahtshamullah Chaudhry, Arslan Afzal, Zauraiz Anjum, Hamza Tahir, Muhammad Sajeel Anwar, Dushyant Singh Dahiya, Muhammad Sohaib Afzal, Gul Nawaz, Amir H Sohail, Muhammad Aziz

**Hassam Ali, Arslan Afzal,** Department of Gastroenterology, East Carolina University Brody School of Medicine, Greenville, NC 27834, United States

**Faisal Inayat, Gul Nawaz,** Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Punjab 54550, Pakistan

**Vishali Moond,** Department of Internal Medicine, Saint Peter's University Hospital and Robert Wood Johnson Medical School, New Brunswick, NJ 08901, United States

**Ahtshamullah Chaudhry,** Department of Internal Medicine, St. Dominic's Hospital, Jackson, MS 39216, United States

**Zauraiz Anjum,** Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, United States

**Hamza Tahir,** Department of Internal Medicine, Jefferson Einstein Hospital, Philadelphia, PA 19141, United States

**Muhammad Sajeel Anwar,** Department of Internal Medicine, UHS Wilson Medical Center, Johnson, NY 13790, United States

**Dushyant Singh Dahiya,** Division of Gastroenterology, Hepatology and Motility, The University of Kansas School of Medicine, Kansas, KS 66160, United States

**Muhammad Sohaib Afzal,** Department of Internal Medicine, Louisiana State University Health, Shreveport, LA 71103, United States

**Amir H Sohail,** Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM 87106, United States

**Muhammad Aziz,** Department of Gastroenterology and Hepatology, The University of Toledo, Toledo, OH 43606, United States

**Author contributions:** Ali H, Inayat F, Moond V, Chaudhry A, Afzal A, and Anjum Z concepted and designed the study, participated in the acquisition of data, interpretation of results, writing of the original draft, and critical revisions of the important intellectual content of the final manuscript; Tahir H, Anwar MS, Dahiya DS, Afzal MS, Nawaz G, and Sohail AH contributed to the analysis and interpretation of results and drafting of the manuscript; Aziz M reviewed, revised, and improved the manuscript by suggesting pertinent modifications; and all authors critically assessed, edited, and approved the final manuscript and are accountable for all aspects of the work.

**Corresponding author: Faisal Inayat, MBBS, Research Scientist,** Department of Internal Medicine, Allama Iqbal Medical College, Allama Shabbir Ahmad Usmani Road, Faisal Town, Lahore, Punjab 54550, Pakistan. faisalinayat@hotmail.com

**Received:** December 30, 2023

**Revised:** February 7, 2024

**Accepted:** March 5, 2024

**Published online:**

**Abstract**

BACKGROUND

Roux-en-Y gastric bypass (RYGB) is a widely recognized bariatric procedure that is particularly beneficial for patients with class III obesity. It aids in significant weight loss and improves obesity-related medical conditions. Despite its effectiveness, postoperative care still has challenges. Clinical evidence shows that venous thromboembolism (VTE) is a leading cause of 30-d morbidity and mortality after RYGB. Therefore, a clear unmet need exists for a tailored risk assessment tool for VTE in RYGB candidates.

AIM

To develop and internally validate a scoring system determining the individualized risk of 30-d VTE in patients undergoing RYGB.

METHODS

Using the 2016–2021 Metabolic and Bariatric Surgery Accreditation Quality Improvement Program, data from 6526 patients (body mass index ≥ 40 kg/m2) who underwent RYGB were analyzed. A backward elimination multivariate analysis identified predictors of VTE characterized by pulmonary embolism and/or deep venous thrombosis within 30 d of RYGB. The resultant risk scores were derived from the coefficients of statistically significant variables. The performance of the model was evaluated using receiver operating curves through 5-fold cross-validation.

RESULTS

Of the 26 initial variables, six predictors were identified. These included a history of chronic obstructive pulmonary disease with a regression coefficient (Coef) of 2.54 (*P* < 0.001), length of stay (Coef 0.08, *P* < 0.001), prior deep venous thrombosis (Coef 1.61, *P* < 0.001), hemoglobin A1c > 7% (Coef 1.19, *P* < 0.001), venous stasis history (Coef 1.43, *P* < 0.001), and preoperative anticoagulation use (Coef 1.24, *P* < 0.001). These variables were weighted according to their regression coefficients in an algorithm that was generated for the model predicting 30-d VTE risk post-RYGB. The risk model's area under the curve (AUC) was 0.79 [95% confidence interval (CI): 0.63-0.81], showing good discriminatory power, achieving a sensitivity of 0.60 and a specificity of 0.91. Without training, the same model performed satisfactorily in patients with laparoscopic sleeve gastrectomy with an AUC of 0.63 (95%CI: 0.62-0.64) and endoscopic sleeve gastroplasty with an AUC of 0.76 (95%CI: 0.75-0.78).

CONCLUSION

This simple risk model uses only six variables to assist clinicians in the preoperative risk stratification of RYGB patients, offering insights into factors that heighten the risk of VTE events.

**Key Words:** Roux-en-Y gastric bypass; Venous thromboembolism; Machine learning; Bariatric surgery; Predictive modeling

Ali H, Inayat F, Moond V, Chaudhry A, Afzal A, Anjum Z, Tahir H, Anwar MS, Dahiya DS, Afzal MS, Nawaz G, Sohail AH, Aziz M. Predicting short-term thromboembolic risk following Roux-en-Y gastric bypass using supervised machine learning. *World J Gastrointest Surg* 2024; In press

**Core Tip:** Venous thromboembolism (VTE) is an uncommon but important cause of morbidity and mortality following Roux-en-Y gastric bypass (RYGB). Clinical evidence regarding VTE risk stratification after RYGB remains limited.Using a multicenter database, this is the first retrospective cross-sectional study that used supervised machine learning to develop and internally validate a scoring system to assess the 30-d individualized risk of VTE post-RYGB. Our model uses only six preoperative variables, including a history of chronic obstructive pulmonary disease, length of stay, previous deep venous thrombosis, hemoglobin A1c > 7%, prior venous stasis, and preoperative anticoagulation use. Our findings may help to improve clinical outcomes and procedural safety for patients undergoing RYGB.

**INTRODUCTION**

Obesity is a chronic, relapsing disease that has numerous physical, psychological, and metabolic ramifications[1]. The World Obesity Atlas 2023 report states that 38% of the global population is currently overweight or obese, and the prevalence is projected to rise to 51% by 2035[2]. In the United States, the rates of severe obesity have increased from 1.5% in 1971/74 to 9% in 2017/20[3]. Recent advances in drug therapy have revolutionized obesity treatment, but anti-obesity medications may have questionable safety and inadequate efficacy for sustained weight loss[4,5]. Therefore, bariatric surgery procedures such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy have gained preeminence over the past decade[6,7]. A systematic review of 26 studies showed that bariatric surgery may be a clinically and financially advantageous choice for patients with moderate and severe obesity when compared to non-surgical therapy[8]. Consequently, the number of bariatric surgery interventions has steadily increased over time[9]. According to estimates by the American Society for Bariatric and Metabolic Surgery, the total bariatric procedure numbers increased from 158000 in 2011 to 262893 in 2021[10]. Compared to conventional, non-surgical treatment of obesity, bariatric surgical interventions reduce the relative risk of death, clinically improve medical comorbidities, and result in long-term weight loss[11-17]. Despite extensive research on effectiveness and safety, there are certain complications linked to bariatric surgery procedures[18-20].

Venous thromboembolism (VTE), such as pulmonary embolism (PE) and deep vein thrombosis (DVT), is an uncommon surgical sequela of bariatric surgery. However, it is a major cause of postoperative morbidity and mortality. The rate of VTE in bariatric patients ranges from 0.3% to 2.4%[21-24]. In a meta-analysis of 71 studies based on 107874 patients, the < 30-d PE rate following bariatric surgery was 1.17%[25]. Although PE has an incidence of around 1%, it accounts for 40% of all 30-d postoperative deaths[26-28]. Therefore, it is one of the major causes of mortality after bariatric surgery. In an analysis of the Nationwide Readmission Database, Mabeza *et al*[29] showed that bariatric surgery patients with VTE had a higher risk of mortality, an increased length of stay, and higher in-patient charges in their index hospital admission. Obesity is a hypercoagulability state, and it also leads to several systemic complications that may increase the risk of VTE[30]. Bariatric surgery involves several complex steps. Factors like long procedure durations, challenging surgery, the necessity for surgical reinterventions, and the need for blood transfusions may also increase VTE risk[31]. It is a preventable cause of morbidity and mortality. Therefore, effective prognostication may help to avoid postoperative VTE in patients undergoing bariatric surgery.

A number of assessment tools have previously been developed to predict the risk of VTE following bariatric surgery[32-37]. However, these models differ significantly in terms of high-risk criteria, predictive performance, and inclusion characteristics[38]. Furthermore, VTE risk factors may also vary based on bariatric surgery procedures, such as sleeve gastrectomy or RYGB[39]. Recent developments in artificial intelligence offer a chance to improve the accuracy of risk stratification through effective analysis of large volumes of patient data. Recently, Hsu *et al*[40] developed a machine learning model that outperformed logistic regression in predicting postoperative gastrointestinal bleeding in bariatric surgery patients. However, machine learning has not been used in VTE risk prediction in bariatric patients. Therefore, to our knowledge, this is the first study to develop and internally validate a 30-d RYGB-specific VTE risk scoring system using supervised machine learning. Our model can help mitigate the risk of VTE by identifying modifiable precipitating factors, setting reasonable expectations, and promoting communication between patients and healthcare providers. Moreover, our findings could contribute to the available clinical evidence, thereby further refining the recommendations for perioperative VTE prophylaxis[41].

**MATERIALS AND METHODS**

***Design and data source***

This retrospective cross-sectional study is based on the Metabolic and Bariatric Surgery Accreditation Quality Improvement Program (MBSAQIP)[42]. It is recognized as the most extensive global repository specifically focused on bariatric surgeries, covering procedures performed from January 2016 to December 2021[42]. All 885 certified centers specializing in bariatric surgeries contribute their complete data for every bariatric procedure. This data encompasses stages before, during, and after the operation, including existing patient conditions and 30-d postoperative results[42]. Identifiable information related to hospitals, patients, or physicians is unavailable due to privacy protocols. Our analysis is based on complete cases documented in the MBSAQIP registry. The database undergoes routine quality checks and removes centers with low 30-d follow-up rates (less than 80%) or more than a 5% rate of data discrepancies[42].

***Population of interest***

This research used data from the MBSAQIP database from 2016 to 2021. Patients with a baseline body mass index (BMI) ≥ 40 kg/m2 who had undergone RYGB were identified. The event of interest was the occurrence of postoperative VTE, such as PE and/or DVT, within 30 d after the procedure. Consistent with prior research, cases including individuals under the age of 18, those with a BMI below the cutoff point, missing or miscoded data, and those who had undergone revision or conversion procedures were excluded[43]. Preselected clinical factors (only preoperative variables) were considered based on existing scientific insights and recent scholarly works[24]. The variables with incomplete data were omitted. A correlation assessment was conducted to screen all potential explanatory variables for collinearity (Supplementary Figure 1). Factors that demonstrated a correlation score above 0.7 were removed. The short list of risk variables included patient demographics, clinical factors, and laboratory results.

***Statistical analysis***

The "pmsampsize" command in the Statistical Software for Data Science (StataCorp LLC, College Station, TX) was used to determine the smallest sample size needed to generate a novel multivariable predictive model with a binary result; the anticipated C-statistic was 0.80, and the possible inclusions for this new predictive model were numbered at 26. The required minimum sample size for the risk assessment was specified as 2108. A backward elimination multivariate regression model was employed to isolate the significant predictors of the 30-d VTE risk with a cutoff *P* value of < 0.05. This method zeroed out the coefficients of less important variables, effectively eliminating them. To estimate the model's predictive quality, a 5-fold cross-validation method was applied. It helps avoid overly optimistic performance evaluations in neglected cases[44]. The area under the curve (AUC) was used to judge the model's discriminatory power for 30-d VTE risk, with values ranging as described[45].

The match between the model-predicted and actual 30-d VTE risk was examined *via* calibration belt plots, enabling a visual comparison between expected and observed frequencies and the orientation of any miscalibration[46]. The plot included a calibration test to determine if any deviations from the line of perfect fit (bisector at 45 degrees) were significant[45,47]. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis guidelines were followed in the development and validation of this prediction model[48].

***Ethical considerations***

The MBSAQIP is based on de-identified aggregated data with accepted privacy standards in accordance with the guidelines for human subject research. In order to comply with privacy regulations, the third party acquired and de-identified the data, ensuring that no individual could be recognized either directly or indirectly. We adhered to all ethical standards in utilizing this dataset for research purposes. Therefore, this study did not require institutional review board approval. Moreover, informed consent did not apply as the patient data were anonymized.

**RESULTS**

A total of 6526 patients were included in the present analysis. The demographic and clinical characteristics are outlined (Table 1). The 30-d VTE rate for RYGB cases was 0.84%. Six out of the 26 predictors were retained by the backward regression for predicting 30-d VTE, including a history of preoperative chronic obstructive pulmonary disease (COPD) with a regression coefficient (Coef) of 2.54 [95% confidence interval (CI): 1.57-3.51, *P* < 0.001], length of stay (Coef 0.08, 95%CI: 0.06-0.11, *P* < 0.001), a history of DVT (Coef 1.62, 95%CI: 0.31-2.92, *P* = 0.015), hemoglobin A1c (HbA1c) > 7% (Coef 1.19, 95%CI: 0.52-1.86, *P* = 0.001), venous stasis history (Coef 1.44, 95%CI: 0.40-2.48, *P* = 0.007), and preoperative anticoagulation (Coef 1.24, 95%CI: 0.01-2.48, *P* = 0.049) (Table 2).

Using this multivariable model, a risk model was inferred based on the six factors weighted by their regression coefficients in the multivariable logistic regression model. It is represented by the following equation: VTE risk score = (2.54 × preoperative COPD) + (0.08 × length of stay) + (1.62 × previous DVT) + (1.19 × HbA1c > 7%) + (1.44 × venous stasis history) + (1.24 × preoperative anticoagulation use) - 5.77. The optimal cutoff point for the risk score was determined using the Youden index. This index maximizes the sum of sensitivity and specificity for each available cutoff and selects the maximum sum. For our risk score model, the optimal cutoff point was approximately -4.2 (high risk *vs* low risk).

With this cutoff, the model yielded a sensitivity of 60% and a specificity of 91%. The area under the receiver operating characteristic curve was 0.79 (95%CI: 0.63-0.80) (Figure 1). Without training, the same model performed satisfactorily in patients with laparoscopic sleeve gastrectomy with an AUC of 0.63 (95%CI: 0.62-0.64) and endoscopic sleeve gastroplasty with an AUC of 0.76 (95%CI: 0.75-0.78). The 95% and 99% confidence levels of the calibration belt plot indicated that there was no discernible miscalibration. At 95% confidence levels (the inner belt or light gray region) and 99% confidence levels (the outer belt or dark gray area), the predicted model probability matched the observed result rate (Figure 2).

**DISCUSSION**

This is the first population-based study that used supervised machine learning to develop and internally validate a scoring system based on only six preoperative variables to assess the individual risk of VTE within the first 30 d post-RYGB. The variables included a history of COPD, length of stay, previous DVT, HbA1c > 7%, venous stasis history, and prior anticoagulation use. Our simple model could aid clinicians in the preoperative risk stratification of RYGB patients for VTE. It may constitute a crucial step to improve clinical outcomes and procedural safety for bariatric patients.

VTE, including PE and DVT, continues to be a significant concern for postoperative morbidity and mortality in patients undergoing bariatric surgery[49]. Existing data suggest that PE affects 0.3%-2% of bariatric patients, and DVT develops in 1%-3% of cases[50,51]. The majority of VTE events following bariatric surgery have been reported after hospital discharge but within the 30-d postoperative period[52]. A number of risk factors have been recognized, including a higher BMI, increased age, male sex, past instances of VTE, obesity-related hypoventilation issues, limited mobility, pulmonary hypertension, surgery duration, and procedure type[53,54]. However, a comprehensive understanding of the VTE risk profile in this setting remains elusive[33,55]. Currently, there is a limited evidence base to construct a risk-adjusted approach for VTE prevention after RYGB. Our study utilized a robust dataset of 6526 patients. A total of 26 variables were initially considered as potential predictors. Eventually, six variables were utilized to create the predictive algorithm. The resulting model exhibited a sensitivity of 60% and a specificity of 91%. This scoring system has pertinent clinical implications as part of a broader risk assessment strategy. Notably, the 30-d incidence rate of VTE following RYGB was 0.84% in our data.

Our study suggested that preoperative COPD is an independent risk factor for VTE after RYGB. A national study revealed that preoperative COPD may double the risk of pulmonary complications after surgery[56]. Lawrence *et al*[57] suggested that symptoms such as diminished breath sounds, extended expiration, decreased oxygen levels, and wheezing or rhonchi upon examination can elevate the risk of postoperative pulmonary complications sixfold. Furthermore, a study by Børvik *et al*[58] revealed that individuals with severe COPD might face an elevated risk of developing secondary VTE and have higher mortality rates in comparison to their counterparts without VTE post-surgery. Similarly, studies suggest the length of hospital stay as an important risk factor for the onset of VTE events in surgical patients[59]. Our investigation also indicated a heightened risk of VTE associated with a longer hospital stay among patients who underwent RYGB.

Previous VTE may serve as one of the predictors of thromboembolic complications in bariatric surgery patients. A case-cohort study revealed that patients who had surgery and were subsequently hospitalized following their initial VTE episode were at an increased risk of developing recurrent in-hospital VTE in comparison to those patients who had a VTE history but did not undergo surgery[60]. Furthermore, in a retrospective cohort study, Bahl *et al*[32] demonstrated that 4.2% of patients with a history of VTE developed recurrent VTE within 30 d of surgery. Nemeth *et al*[61] revealed that patients with a history of VTE undergoing gastrointestinal surgeries had a high risk of VTE recurrence at six months (hazard ratio, 8.4; 95%CI: 4.0-17.8). Similarly, Chao *et al*[62] also showed in their retrospective study that a history of VTE was the greatest driver of VTE post-bariatric surgery. Our results also validated these findings, as patients with a history of VTE were found to have a significantly increased risk of developing a recurrent VTE post-RYGB. Considering that VTE is a preventable cause of inpatient death and 60% of VTE incidents occur during or post-hospitalization, it is crucial to recognize the elevated risk of recurrence related to surgical procedures in patients with a prior history of VTE[63]. Previous research has demonstrated that venous stasis disease may also increase VTE risk in patients undergoing bariatric surgery procedures[64,65]. Furthermore, several studies revealed that patients on preoperative anticoagulation had a higher risk of VTE following bariatric surgery[66,67]. Our study also showed venous stasis and preoperative anticoagulation use as predictors of VTE in RYGB patients.

Studies evaluating the impact of glycemic control on the risk of VTE in patients with diabetes mellitus (DM) showed marked heterogeneity. Some studies have identified a positive correlation between increased glucose levels and the risk of developing VTE[68,69]. However, Lerstad *et al*[70] found no such association in their multivariable analysis of a Norwegian population-based cohort. Notably, their results demonstrated that the risk of VTE climbed by 5% per one standard deviation (0.7%) elevation of HbA1c level[70]. In a case-control analysis, Charlier *et al*[71] suggested that women with type 2 DM with HbA1c levels above 7% might have a marginally elevated risk of unprovoked VTE compared to those with HbA1c levels between 6.5% and 7%. However, no studies have specifically delved into the occurrence of VTE and its related risk factors post-bariatric surgery in diabetic patients. Our findings indicate a statistically significant increase in VTE risk among patients with an HbA1c level exceeding 7%.

The use of stepwise backward regression in this study represents a departure from traditional logistic regression approaches, adding a layer of complexity and predictive accuracy. This method allowed for efficient variable selection, pinpointing the most relevant risk factors from a broad set of potential predictors. This streamlining is particularly valuable in clinical settings where quick and accurate risk assessment can have a significant impact on patient education and outcomes. A few studies in the literature, including randomized controlled trials, have used machine learning to predict VTE in patients with allogeneic transplants or coronavirus disease 2019[72,73]. However, no such study has been conducted to predict the risk of VTE among patients undergoing RYGB.

Sheikhtaheri *et al*[74] formulated a model using an artificial neural network (ANN) algorithm to forecast complications after one-anastomosis gastric bypass surgery within a 90-d timeframe. This model accounted for complications like bleeding, leakage at the anastomotic site, obstruction, an abscess within the abdomen, and PE[74]. The prediction model incorporated 32 factors, including age, BMI, smoking habits, and laboratory test outcomes[74]. Remarkably, the model showcased its peak accuracy (AUC score: 0.98) during the first 10 d post-surgery[74]. Similarly, Cao *et al*[75] utilized various machine learning methods to identify significant complications occurring within a month of bariatric surgery. Their study incorporated algorithms like decision trees, random forests, gradient boosting, support vector machine (SVM), and ANN[75]. The outcomes demonstrated model performances as follows: the decision tree achieved an accuracy of 92% with an AUC of 0.5, the random forest had 95% accuracy with 0.51 AUC, gradient boosting presented 96% accuracy with 0.58 AUC, SVM recorded 96% accuracy with an AUC of 0.5, and ANN reported 96% accuracy with a 0.54 AUC[75].

Cao *et al*[76] utilized ANN and convolutional neural network (CNN) models to forecast significant complications within 30 d post-bariatric surgery. They categorized serious complications using the Clavien-Dindo classification of grade 3b or above, which includes issues like anastomotic leakage, organ failure, or even death[76]. The effectiveness of each model was measured using accuracy and AUC metrics. Specifically, the ANN model achieved 84% accuracy with an AUC of 0.54, while the CNN model reached 95% accuracy with an AUC of 0.57 in predicting post-surgery complications[76]. Based on a cohort of 101721 laparoscopic sleeve gastrectomy patients, Wise *et al*[77] predicted a readmission rate of 3.1%, a reoperation and reintervention rate of 8.7%, and a mortality rate of 0.07% within 30 d following the procedure. Utilizing an ANN model, they identified an AUC of 0.59. Additionally, the following seven factors appeared to be necessary for the prediction of 30-d morbidity and mortality: Age, race, BMI, hypertension, DM, functional capacity, and a history of prior surgery[77].

The published research indicates that despite an increase in comprehensive studies on RYGB surgery, prediction of short- and long-term complications remains difficult. The American Society of Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders have updated indications for bariatric surgery[78]. As a result, it is expected that the bariatric surgery procedure numbers will further increase. It underscores the clinical importance of a meticulous evaluation of all probable risk factors and a tailored algorithm to prevent complications. This is one area where supervised machine learning techniques might be particularly beneficial to reduce the risk of VTE after bariatric surgery. Our study shows that crafting an algorithm to evaluate the 30-d VTE risk following RYGB would enhance the understanding of related factors and equip the surgeon and the patient with the insights needed for informed decision-making.

***Limitations***

There are certain limitations to our study. The primary factor was the lack of exact predictors that could improve the accuracy of the risk model, such as hospital-level data. Moreover, gathering detailed data on specific procedures and center volumes posed additional difficulties. The applicability of our model to a broader global population might be restricted as the sample population only involved patients from North America. Nonetheless, it is important to highlight that the study used robust 5-fold cross-validation, reinforcing the reliability of the predictive model despite these limitations. More studies should aim to validate the model in a broader clinical context and potentially expand its application to other surgical procedures. It could serve as a VTE risk prediction tool for bariatric surgery patients, particularly in resource-limited settings. It is most effective when used as a part of a broader risk assessment strategy, where individuals who are classified as high-risk may also be subjected to additional confirmatory tests. Future studies could also explore improving the model's sensitivity without compromising its specificity.

**CONCLUSION**

This study utilized supervised machine learning to develop a preoperative risk stratification model for VTE in patients undergoing RYGB. Our simple risk model predicting 30-d VTE risk after the RYGB procedure incorporated only six variables, including a history of COPD, length of stay, prior DVT, HbA1c, a history of venous stasis, and preoperative anticoagulation use. This model has pertinent clinical implications as a preliminary VTE risk assessment method for RYGB candidates. Therefore, our results may help to avoid VTE-related morbidity and mortality in patients undergoing bariatric surgery. Future population-based studies are warranted to externally validate our findings.

**ARTICLE HIGHLIGHTS**

***Research background***

The escalating global prevalence of obesity has prompted the advancement of various therapeutic interventions. Roux-en-Y gastric bypass (RYGB) has established efficacy, particularly for class III obesity. However, despite its benefits, postoperative complications like venous thromboembolism (VTE) remain a significant concern due to their contribution to morbidity and mortality within 30 d post-surgery. This study addresses the critical gap in clinical risk stratification and predictive modeling for VTE post-RYGB.

***Research motivation***

This research is driven by the need to develop a simple and reliable RYBG-specific predictive model for VTE. The goal is to mitigate the 30-d morbidity and mortality associated with VTE by enabling clinicians to identify high-risk individuals through a validated scoring system, thereby guiding preventive strategies and optimizing patient management post-RYGB.

***Research objectives***

The primary objective of this study was to construct and internally validate a scoring system for the prediction of individualized VTE risk within 30 d after RYGB. By focusing on preoperative variables, the study aimed to deliver a practical tool for clinicians to enhance preoperative risk stratification and improve overall patient outcomes.

***Research methods***

Utilizing data from the Metabolic and Bariatric Surgery Accreditation Quality Improvement Program database, this research used a backward elimination multivariate analysis to determine the predictors of VTE. The performance of the model was validated using receiver operating curves and 5-fold cross-validation.

***Research results***

Our study based on multivariate analysis identified six significant predictors: A history of chronic obstructive pulmonary disease, length of stay, prior deep venous thrombosis, hemoglobin A1c, a history of venous stasis, and preoperative anticoagulation use, each quantified by robust regression coefficients. The derived risk model exhibited commendable predictive performance with an area under the curve of 0.79, sensitivity of 0.60, and specificity of 0.91. This model also demonstrated satisfactory predictive capability in laparoscopic sleeve gastrectomy and endoscopic sleeve gastroplasty populations.

***Research conclusions***

Our study concludes that the devised risk model, underpinned by supervised machine learning, constitutes a significant step forward in preoperative risk stratification for VTE. It provides a clinically relevant, evidence-based tool that simplifies the assessment process without compromising accuracy through backward elimination multivariate analysis. This approach distills a comprehensive variable set down to six critical predictors, advancing the precision of risk stratification for VTE post-RYGB. The innovation of this study lies in its machine learning-based algorithm, which demonstrates a significant improvement in the predictive accuracy of short-term thromboembolic complications when compared to traditional statistical models.

***Research perspectives***

Our model stands out for its simplicity and clinical applicability, potentially aiding in the preoperative assessment of VTE risk and the tailoring of prophylactic measures. Future research should focus on external validation of the scoring system across diverse populations and healthcare settings. Moreover, incorporating additional variables, such as perioperative data, may further refine the predictive capability of the model. Expansion to include other surgical procedures may also be considered, broadening the scope and impact of the research findings.

**REFERENCES**

1 **Allison DB**, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, Finkelstein EA, Jensen MD, Tremblay A. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. *Obesity (Silver Spring)* 2008; **16**: 1161-1177 [PMID: 18464753 DOI: 10.1038/oby.2008.231]

2 **Lobstein T**, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023. [cited 27 December 2023] Available from: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023

3 **Kranjac AW**, Kranjac D. Explaining adult obesity, severe obesity, and BMI: Five decades of change. *Heliyon* 2023; **9**: e16210 [PMID: 37251838 DOI: 10.1016/j.heliyon.2023.e16210]

4 **Chakhtoura M**, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. *EClinicalMedicine* 2023; **58**: 101882 [PMID: 36992862 DOI: 10.1016/j.eclinm.2023.101882]

5 **Müller TD**, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. *Nat Rev Drug Discov* 2022; **21**: 201-223 [PMID: 34815532 DOI: 10.1038/s41573-021-00337-8]

6 **Kamiński M**, Miętkiewska-Dolecka M, Kręgielska-Narożna M, Bogdański P. Popularity of Surgical and Pharmacological Obesity Treatment Methods Searched by Google Users: the Retrospective Analysis of Google Trends Statistics in 2004-2022. *Obes Surg* 2024; **34**: 882-891 [PMID: 38103152 DOI: 10.1007/s11695-023-06971-y]

7 **Gulinac M**, Miteva DG, Peshevska-Sekulovska M, Novakov IP, Antovic S, Peruhova M, Snegarova V, Kabakchieva P, Assyov Y, Vasilev G, Sekulovski M, Lazova S, Tomov L, Velikova T. Long-term effectiveness, outcomes and complications of bariatric surgery. *World J Clin Cases* 2023; **11**: 4504-4512 [PMID: 37469732 DOI: 10.12998/wjcc.v11.i19.4504]

8 **Picot J**, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. *Health Technol Assess* 2009; **13**: 1-190, 215-357, iii-iiv [PMID: 19726018 DOI: 10.3310/hta13410]

9 **Lazzati A**. Epidemiology of the surgical management of obesity. *J Visc Surg* 2023; **160**: S3-S6 [PMID: 36725453 DOI: 10.1016/j.jviscsurg.2022.12.004]

10 **American Society for Bariatric and Metabolic Surgery**. Estimate of Bariatric Surgery Numbers, 2011-2021. [Cited 27 December 2023] Available from: https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers

11 **Gloy VL**, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery *versus* non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ* 2013; **347**: f5934 [PMID: 24149519 DOI: 10.1136/bmj.f5934]

12 **Maciejewski ML**, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, Livingston EH, Olsen MK. Bariatric Surgery and Long-term Durability of Weight Loss. *JAMA Surg* 2016; **151**: 1046-1055 [PMID: 27579793 DOI: 10.1001/jamasurg.2016.2317]

13 **Adams TD**, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, Gutierrez JM, Frogley SJ, Ibele AR, Brinton EA, Hopkins PN, McKinlay R, Simper SC, Hunt SC. Weight and Metabolic Outcomes 12 Years after Gastric Bypass. *N Engl J Med* 2017; **377**: 1143-1155 [PMID: 28930514 DOI: 10.1056/NEJMoa1700459]

14 **Olbers T**, Beamish AJ, Gronowitz E, Flodmark CE, Dahlgren J, Bruze G, Ekbom K, Friberg P, Göthberg G, Järvholm K, Karlsson J, Mårild S, Neovius M, Peltonen M, Marcus C. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. *Lancet Diabetes Endocrinol* 2017; **5**: 174-183 [PMID: 28065734 DOI: 10.1016/S2213-8587(16)30424-7]

15 **Wu T**, Wong CKH, Lui DTW, Wong SKH, Lam CLK, Chung MSH, McAllister DA, Welbourn R, Dixon JB. Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials. *BJS Open* 2023; **7** [PMID: 37542473 DOI: 10.1093/bjsopen/zrad077]

16 **Madani S**, Shahsavan M, Pazouki A, Setarehdan SA, Yarigholi F, Eghbali F, Shahmiri SS, Kermansaravi M. Five-Year BAROS Score Outcomes for Roux-en-Y Gastric Bypass, One Anastomosis Gastric Bypass, and Sleeve Gastrectomy: a Comparative Study. *Obes Surg* 2024; **34**: 487-493 [PMID: 38147191 DOI: 10.1007/s11695-023-07015-1]

17 **Ontario Health (Quality)**. Bariatric Surgery for Adults With Class I Obesity and Difficult-to-Manage Type 2 Diabetes: A Health Technology Assessment. *Ont Health Technol Assess Ser* 2023; **23**: 1-151 [PMID: 38130940]

18 **Kassir R**, Debs T, Blanc P, Gugenheim J, Ben Amor I, Boutet C, Tiffet O. Complications of bariatric surgery: Presentation and emergency management. *Int J Surg* 2016; **27**: 77-81 [PMID: 26808323 DOI: 10.1016/j.ijsu.2016.01.067]

19 **Lim R**, Beekley A, Johnson DC, Davis KA. Early and late complications of bariatric operation. *Trauma Surg Acute Care Open* 2018; **3**: e000219 [PMID: 30402562 DOI: 10.1136/tsaco-2018-000219]

20 **Goel R**, Nasta AM, Goel M, Prasad A, Jammu G, Fobi M, Ismail M, Raj P, Palaniappan R, Aggarwal S, Bindal V, Katakwar A, Vennapusa A, Bhasker AG, Peters A, Goel D, Bedi D, Palep J, Kona L, Mehrotra M, Baijal M, Bhandari M, Dukkipati N, Wadhawan R, Baig S, Pattanshetti S, Ugale S. Complications after bariatric surgery: A multicentric study of 11,568 patients from Indian bariatric surgery outcomes reporting group. *J Minim Access Surg* 2021; **17**: 213-220 [PMID: 32964881 DOI: 10.4103/jmas.JMAS\_12\_20]

21 **Winegar DA**, Sherif B, Pate V, DeMaria EJ. Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database. *Surg Obes Relat Dis* 2011; **7**: 181-188 [PMID: 21421182 DOI: 10.1016/j.soard.2010.12.008]

22 **Carvalho L**, Almeida RF, Nora M, Guimarães M. Thromboembolic Complications After Bariatric Surgery: Is the High Risk Real? *Cureus* 2023; **15**: e33444 [PMID: 36628392 DOI: 10.7759/cureus.33444]

23 **Hamad GG**, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. *Obes Surg* 2005; **15**: 1368-1374 [PMID: 16354513 DOI: 10.1381/096089205774859245]

24 **Froehling DA**, Daniels PR, Mauck KF, Collazo-Clavell ML, Ashrani AA, Sarr MG, Petterson TM, Heit JA. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study. *Obes Surg* 2013; **23**: 1874-1879 [PMID: 24022324 DOI: 10.1007/s11695-013-1073-1]

25 **Chang SH**, Freeman NLB, Lee JA, Stoll CRT, Calhoun AJ, Eagon JC, Colditz GA. Early major complications after bariatric surgery in the USA, 2003-2014: a systematic review and meta-analysis. *Obes Rev* 2018; **19**: 529-537 [PMID: 29266740 DOI: 10.1111/obr.12647]

26 **Stein PD**, Matta F. Pulmonary embolism and deep venous thrombosis following bariatric surgery. *Obes Surg* 2013; **23**: 663-668 [PMID: 23404239 DOI: 10.1007/s11695-012-0854-2]

27 **Jamal MH**, Corcelles R, Shimizu H, Kroh M, Safdie FM, Rosenthal R, Brethauer SA, Schauer PR. Thromboembolic events in bariatric surgery: a large multi-institutional referral center experience. *Surg Endosc* 2015; **29**: 376-380 [PMID: 24986019 DOI: 10.1007/s00464-014-3678-4]

28 **El Ansari W**, El-Ansari K. Missing something? A scoping review of venous thromboembolic events and their associations with bariatric surgery. Refining the evidence base. *Ann Med Surg (Lond)* 2020; **59**: 264-273 [PMID: 33133579 DOI: 10.1016/j.amsu.2020.08.014]

29 **Mabeza RM**, Lee C, Verma A, Park MG, Darbinian K, Darbinian S, Yetasook A, Benharash P. Factors and Outcomes Associated With Venous Thromboembolism Following Bariatric Surgery. *Am Surg* 2022; **88**: 2525-2530 [PMID: 35611767 DOI: 10.1177/00031348221103645]

30 **Yang G**, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: A review. *Open J Prev Med* 2012; **2**: 499-509 [PMID: 26236563 DOI: 10.4236/ojpm.2012.24069]

31 **Hamad GG**, Bergqvist D. Venous thromboembolism in bariatric surgery patients: an update of risk and prevention. *Surg Obes Relat Dis* 2007; **3**: 97-102 [PMID: 17196437 DOI: 10.1016/j.soard.2006.10.002]

32 **Bahl V**, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Ann Surg* 2010; **251**: 344-350 [PMID: 19779324 DOI: 10.1097/SLA.0b013e3181b7fca6]

33 **Finks JF**, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M, Birkmeyer JD, Birkmeyer NJ; Michigan Bariatric Surgery Collaborative; Center for Healthcare Outcomes and Policy. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. *Ann Surg* 2012; **255**: 1100-1104 [PMID: 22566018 DOI: 10.1097/SLA.0b013e31825659d4]

34 **Dang JT**, Switzer N, Delisle M, Laffin M, Gill R, Birch DW, Karmali S. Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database. *Surg Endosc* 2019; **33**: 821-831 [PMID: 30003351 DOI: 10.1007/s00464-018-6348-0]

35 **Aminian A**, Andalib A, Khorgami Z, Cetin D, Burguera B, Bartholomew J, Brethauer SA, Schauer PR. Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis. *Ann Surg* 2017; **265**: 143-150 [PMID: 28009739 DOI: 10.1097/SLA.0000000000001686]

36 **Cronin M**, Dengler N, Krauss ES, Segal A, Wei N, Daly M, Mota F, Caprini JA. Completion of the Updated Caprini Risk Assessment Model (2013 Version). *Clin Appl Thromb Hemost* 2019; **25**: 1076029619838052 [PMID: 30939900 DOI: 10.1177/1076029619838052]

37 **Edwards MA**, Spaulding A, Brennan E, Elli EF. Risk stratified venous thromboembolism prophylaxis in bariatric patients using a Caprini assessment: practice patterns and opportunities for improvement. *Surg Obes Relat Dis* 2024; **20**: 221-234 [PMID: 37891100 DOI: 10.1016/j.soard.2023.09.018]

38 **Imbus JR**, Jung AD, Davis S Jr, Oyefule OO, Patel AD, Serrot FJ, Stetler JL, Majumdar MC, Papandria D, Diller ML, Srinivasan JK, Lin E, Hechenbleikner EM. Extended postoperative venous thromboembolism prophylaxis after bariatric surgery: a comparison of existing risk-stratification tools and 5-year MBSAQIP analysis. *Surg Obes Relat Dis* 2023; **19**: 808-816 [PMID: 37353413 DOI: 10.1016/j.soard.2023.04.329]

39 **Cornejo J**, Gunturu NS, Castillo-Larios R, Elli EF. Do sleeve gastrectomy and Roux-en-Y gastric bypass have different venous thromboembolism risk factors? Creation of 30-day Bariatric Hypercoagulation Score. *Surg Obes Relat Dis* 2023; **19**: 1246-1252 [PMID: 37468337 DOI: 10.1016/j.soard.2023.05.026]

40 **Hsu JL**, Chen KA, Butler LR, Bahraini A, Kapadia MR, Gomez SM, Farrell TM. Application of machine learning to predict postoperative gastrointestinal bleed in bariatric surgery. *Surg Endosc* 2023; **37**: 7121-7127 [PMID: 37311893 DOI: 10.1007/s00464-023-10156-0]

41 **Aminian A**, Vosburg RW, Altieri MS, Hinojosa MW, Khorgami Z; American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery. *Surg Obes Relat Dis* 2022; **18**: 165-174 [PMID: 34896011 DOI: 10.1016/j.soard.2021.10.023]

42 **American College of Surgeons**. Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. [cited 26 December 2023]. Available from: https://www.facs.org/quality-programs/mbsaqip

43 **Ali H**, Inayat F, Malik TF, Patel P, Nawaz G, Taj S, Rehman AU, Afzal A, Ishtiaq R, Afzal MS, Advani R, Watson RR. Operator-specific outcomes in endoscopic sleeve gastroplasty: a propensity-matched analysis of the US population using a multicenter database. *Proc (Bayl Univ Med Cent)* 2023; **36**: 592-599 [PMID: 37614858 DOI: 10.1080/08998280.2023.2228180]

44 **Steyerberg EW**, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. *Eur Heart J* 2014; **35**: 1925-1931 [PMID: 24898551 DOI: 10.1093/eurheartj/ehu207]

45 **Steyerberg EW**, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology* 2010; **21**: 128-138 [PMID: 20010215 DOI: 10.1097/EDE.0b013e3181c30fb2]

46 **Fenlon C**, O'Grady L, Doherty ML, Dunnion J. A discussion of calibration techniques for evaluating binary and categorical predictive models. *Prev Vet Med* 2018; **149**: 107-114 [PMID: 29290291 DOI: 10.1016/j.prevetmed.2017.11.018]

47 **Nattino G**, Finazzi S, Bertolini G. A new calibration test and a reappraisal of the calibration belt for the assessment of prediction models based on dichotomous outcomes. *Stat Med* 2014; **33**: 2390-2407 [PMID: 24497413 DOI: 10.1002/sim.6100]

48 **Collins GS**, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann Intern Med* 2015; **162**: 55-63 [PMID: 25560714 DOI: 10.7326/M14-0697]

49 **Morino M**, Toppino M, Forestieri P, Angrisani L, Allaix ME, Scopinaro N. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. *Ann Surg* 2007; **246**: 1002-7; discussion 1007-9 [PMID: 18043102 DOI: 10.1097/SLA.0b013e31815c404e]

50 **Sapala JA**, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. *Obes Surg* 2003; **13**: 819-825 [PMID: 14738663 DOI: 10.1381/096089203322618588]

51 **Prystowsky JB**, Morasch MD, Eskandari MK, Hungness ES, Nagle AP. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. *Surgery* 2005; **138**: 759-63; discussion 763-5 [PMID: 16269306 DOI: 10.1016/j.surg.2005.07.024]

52 **Helm MC**, Simon K, Higgins R, Kindel TL, Gould JC. Perioperative complications increase the risk of venous thromboembolism following bariatric surgery. *Am J Surg* 2017; **214**: 1135-1140 [PMID: 28958647 DOI: 10.1016/j.amjsurg.2017.07.034]

53 **O'Connor K**, Garcia Whitlock AE, Tewksbury C, Williams NN, Dumon KR. Risk factors for postdischarge venous thromboembolism among bariatric surgery patients and the evolving approach to extended thromboprophylaxis with enoxaparin. *Surg Obes Relat Dis* 2021; **17**: 1218-1225 [PMID: 33814315 DOI: 10.1016/j.soard.2021.02.023]

54 **Wesley Vosburg R**, Druar NM, Kim JJ. Factors Associated with Increased Risk for Pulmonary Embolism After Metabolic and Bariatric Surgery: Analysis of Nearly One Million Patients. *Obes Surg* 2022; **32**: 2433-2437 [PMID: 35568750 DOI: 10.1007/s11695-022-06102-z]

55 **Becattini C**, Agnelli G, Manina G, Noya G, Rondelli F. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. *Surg Obes Relat Dis* 2012; **8**: 108-115 [PMID: 22014482 DOI: 10.1016/j.soard.2011.09.005]

56 **Gupta H**, Ramanan B, Gupta PK, Fang X, Polich A, Modrykamien A, Schuller D, Morrow LE. Impact of COPD on postoperative outcomes: results from a national database. *Chest* 2013; **143**: 1599-1606 [PMID: 23287892 DOI: 10.1378/chest.12-1499]

57 **Lawrence VA**, Cornell JE, Smetana GW; American College of Physicians. Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: systematic review for the American College of Physicians. *Ann Intern Med* 2006; **144**: 596-608 [PMID: 16618957 DOI: 10.7326/0003-4819-144-8-200604180-00011]

58 **Børvik T**, Brækkan SK, Enga K, Schirmer H, Brodin EE, Melbye H, Hansen JB. COPD and risk of venous thromboembolism and mortality in a general population. *Eur Respir J* 2016; **47**: 473-481 [PMID: 26585434 DOI: 10.1183/13993003.00402-2015]

59 **Salomon B**, Dasa V, Krause PC, Hall L, Chapple AG. Hospital Length of Stay Is Associated With Increased Likelihood for Venous Thromboembolism After Total Joint Arthroplasty. *Arthroplast Today* 2021; **8**: 254-257.e1 [PMID: 34095400 DOI: 10.1016/j.artd.2020.12.025]

60 **Heit JA**, Lahr BD, Ashrani AA, Petterson TM, Bailey KR. Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. *Thromb Res* 2015; **136**: 298-307 [PMID: 26143712 DOI: 10.1016/j.thromres.2015.06.030]

61 **Nemeth B**, Lijfering WM, Nelissen RGHH, Schipper IB, Rosendaal FR, le Cessie S, Cannegieter SC. Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism. *JAMA Netw Open* 2019; **2**: e193690 [PMID: 31074822 DOI: 10.1001/jamanetworkopen.2019.3690]

62 **Chao GF**, Montgomery JR, Abou Azar S, Telem DA. Venous thromboembolism: risk factors in the sleeve gastrectomy era. *Surg Obes Relat Dis* 2021; **17**: 1905-1911 [PMID: 34389247 DOI: 10.1016/j.soard.2021.06.022]

63 **Jha AK**, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. *BMJ Qual Saf* 2013; **22**: 809-815 [PMID: 24048616 DOI: 10.1136/bmjqs-2012-001748]

64 **Carmody BJ**, Sugerman HJ, Kellum JM, Jamal MK, Johnson JM, Carbonell AM, Maher JW, Wolfe LG, DeMaria EJ. Pulmonary embolism complicating bariatric surgery: detailed analysis of a single institution's 24-year experience. *J Am Coll Surg* 2006; **203**: 831-837 [PMID: 17116551 DOI: 10.1016/j.jamcollsurg.2006.08.020]

65 **Sugerman HJ**, Sugerman EL, Wolfe L, Kellum JM Jr, Schweitzer MA, DeMaria EJ. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. *Ann Surg* 2001; **234**: 41-46 [PMID: 11460821 DOI: 10.1097/00000658-200107000-00007]

66 **Altieri MS**, Yang J, Zhu C, Konstantinos Spaniolas L, Talamini MA, Pryor AD. Preoperative anticoagulation in patients undergoing bariatric surgery is associated with worse outcomes. *Surg Endosc* 2020; **34**: 4177-4184 [PMID: 31617101 DOI: 10.1007/s00464-019-07191-1]

67 **Modasi A**, Dang JT, Afraz S, Hefler J, Switzer N, Birch DW, Karmali S. Bariatric Surgery Outcomes in Patients on Preoperative Therapeutic Anticoagulation: an Analysis of the 2015 to 2017 MBSAQIP. *Obes Surg* 2019; **29**: 3432-3442 [PMID: 31278654 DOI: 10.1007/s11695-019-04064-3]

68 **Bell EJ**, Selvin E, Lutsey PL, Nambi V, Cushman M, Folsom AR. Glycemia (hemoglobin A1c) and incident venous thromboembolism in the Atherosclerosis Risk in Communities cohort study. *Vasc Med* 2013; **18**: 245-250 [PMID: 24165467 DOI: 10.1177/1358863X13506764]

69 **Hermanides J**, Cohn DM, Devries JH, Kamphuisen PW, Huijgen R, Meijers JC, Hoekstra JB, Büller HR. Venous thrombosis is associated with hyperglycemia at diagnosis: a case-control study. *J Thromb Haemost* 2009; **7**: 945-949 [PMID: 19422464 DOI: 10.1111/j.1538-7836.2009.03442.x]

70 **Lerstad G**, Brodin EE, Enga KF, Jorde R, Schirmer H, Njølstad I, Svartberg J, Braekkan SK, Hansen JB. Hyperglycemia, assessed according to HbA1c , and future risk of venous thromboembolism: the Tromsø study. *J Thromb Haemost* 2014; **12**: 313-319 [PMID: 24382156 DOI: 10.1111/jth.12498]

71 **R Charlier SH**, Meier C, Jick SS, Meier CR, Becker C. Association between glycemic control and risk of venous thromboembolism in diabetic patients: a nested case-control study. *Cardiovasc Diabetol* 2022; **21**: 2 [PMID: 34983504 DOI: 10.1186/s12933-021-01432-1]

72 **Deng RX**, Zhu XL, Zhang AB, He Y, Fu HX, Wang FR, Mo XD, Wang Y, Zhao XY, Zhang YY, Han W, Chen H, Chen Y, Yan CH, Wang JZ, Han TT, Chen YH, Chang YJ, Xu LP, Huang XJ, Zhang XH. Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients. *Transplant Cell Ther* 2023; **29**: 57.e1-57.e10 [PMID: 36272528 DOI: 10.1016/j.jtct.2022.10.007]

73 **Lee Y**, Jehangir Q, Lin CH, Li P, Sule AA, Poisson L, Balijepally V, Halabi AR, Patel K, Krishnamoorthy G, Nair GB. 3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. *J Clin Med* 2022; **11**[PMID: 35887713 DOI: 10.3390/jcm11143949]

74 **Sheikhtaheri A**, Orooji A, Pazouki A, Beitollahi M. A Clinical Decision Support System for Predicting the Early Complications of One-Anastomosis Gastric Bypass Surgery. *Obes Surg* 2019; **29**: 2276-2286 [PMID: 31028626 DOI: 10.1007/s11695-019-03849-w]

75 **Cao Y**, Fang X, Ottosson J, Näslund E, Stenberg E. A Comparative Study of Machine Learning Algorithms in Predicting Severe Complications after Bariatric Surgery. *J Clin Med* 2019; **8** [PMID: 31083643 DOI: 10.3390/jcm8050668]

76 **Cao Y**, Montgomery S, Ottosson J, Näslund E, Stenberg E. Deep Learning Neural Networks to Predict Serious Complications After Bariatric Surgery: Analysis of Scandinavian Obesity Surgery Registry Data. *JMIR Med Inform* 2020; **8**: e15992 [PMID: 32383681 DOI: 10.2196/15992]

77 **Wise ES**, Amateau SK, Ikramuddin S, Leslie DB. Prediction of thirty-day morbidity and mortality after laparoscopic sleeve gastrectomy: data from an artificial neural network. *Surg Endosc* 2020; **34**: 3590-3596 [PMID: 31571034 DOI: 10.1007/s00464-019-07130-0]

78 **Eisenberg D**, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, de Luca M, Faria SL, Goodpaster KPS, Haddad A, Himpens JM, Kow L, Kurian M, Loi K, Mahawar K, Nimeri A, O'Kane M, Papasavas PK, Ponce J, Pratt JSA, Rogers AM, Steele KE, Suter M, Kothari SN. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. *Obes Surg* 2023; **33**: 3-14 [PMID: 36336720 DOI: 10.1007/s11695-022-06332-1]

**Footnotes**

**Institutional review board statement:** The Metabolic and Bariatric Surgery Accreditation Quality Improvement Program database is based on de-identified aggregated data with accepted privacy standards. This database does not report patient identifiers, clinician information, or hospital locations. This study did not require institutional review board approval.

**Informed consent statement:** Participants were not required to give informed consent to this retrospective study since the analysis of baseline characteristics used anonymized clinical data.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American College of Gastroenterology; American Gastroenterological Association; American Society for Gastrointestinal Endoscopy.

**Peer-review started:** December 30, 2023

**First decision:** January 16, 2024

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Soldera J, Brazil **S-Editor:** Qu XL **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Receiver operating characteristic curve with mean cross-validated area under the curve after 5-fold-cross validation.** Area under the curve: 0.79 (95%CI: 0.62, 0.80). ROC: Receiver operating characteristic; CvAUC: Cross-validated area under the curve.



**Figure 2 Calibration belt reporting no area of significant miscalibration at 95% and 99% confidence levels.**

**Table 1 Baseline characteristic and clinical outcomes of included patients**

|  |  |
| --- | --- |
| **Factor** | **Value** |
| N | 6526 |
| Postoperative VTE within 30 d (%) | 49 (0.8) |
| Age, median (IQR) | 44 (36.1, 52.81) |
| Age > 50 yr (%) | 2083 (31.9) |
| Female gender (%) | 5282 (80.9) |
| Preop GERD requiring medication (%) | 2477 (38.0) |
| Preop history of MI (%) | 67 (1.0) |
| Previous PCI (%) | 140 (2.1) |
| Previous cardiac surgery (%) | 48 (0.7) |
| Preop hypertensive requiring medication (%) | 3340 (51.2) |
| Preop hyperlipidemia (%) | 1691 (25.9) |
| Preop weight closest to bariatric surgery, median (IQR) | 287 (256, 329) |
| Preop BMI closest to bariatric surgery, median (IQR) | 47.61 (44.26, 51.75) |
| Preop vein thrombosis (%) | 128 (2.0) |
| Preop venous stasis (%) | 195 (3.0) |
| Preop requiring or on dialysis (%) | 7 (0.1) |
| Preop renal insufficiency/CKD (%) | 56 (0.9) |
| Preop therapeutic anticoagulation (%) | 201 (3.1) |
| Previous foregut surgery (%) | 710 (10.9) |
| Current smoker within 1 yr (%) | 546 (8.4) |
| Preop history of COPD (%) | 126 (1.9) |
| Preop obstructive sleep apnea | 3196 (49.0) |
| Preop steroid/immunosuppressant use for chronic condition (%) | 113 (1.7) |
| Preop history of IVC filter placement (%) | 25 (0.4) |
| Preop history of DM (%) | 2009 (30.8) |
| Preop albumin (g/dL), median (IQR) | 3.9 (3.4, 4.2) |
| Preop serum creatinine (mg/dL), median (IQR) | 0.77 (0.69, 0.85) |
| Preop hematocrit (%), median (IQR) | 40.3 (37.7, 42.8) |
| Preop hemoglobin A1c > 7% | 741 (11.4) |

VTE: Venous thromboembolism; Preop: Preoperative; GERD: Gastroesophageal reflux disease; MI: Myocardial infarction; PCI: Primary coronary intervention; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; IVC: Inferior vena cava; DM: Diabetes mellitus.

**Table 2 The proposed prediction model for 30-d risk of venous thromboembolism in patients undergoing Roux-en-Y gastric bypass**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Regression coefficient** | **Standard error** | ***t* value** | ***P* value** | **95% confidence interval (lower)** | **95% confidence interval (upper)** |
| Preoperative COPD  | 2.54 | 0.49 | 5.15 | 0 | 1.57 | 3.51 |
| Length of stay | 0.08 | 0.01 | 6.24 | 0 | 0.06 | 0.11 |
| Deep vein thrombosis history | 1.62 | 0.67 | 2.42 | 0.02 | 0.31 | 2.92 |
| Hemoglobin A1c level | 1.19 | 0.34 | 3.47 | 0 | 0.52 | 1.86 |
| History of venous stasis | 1.44 | 0.53 | 2.7 | 0.01 | 0.4 | 2.48 |
| Preoperative anticoagulation use | 1.24 | 0.63 | 1.97 | 0.05 | 0.01 | 2.48 |
| Model constant | -5.77 | 0.28 | -20.61 | 0 | -6.32 | -5.22 |

COPD: Chronic obstructive pulmonary disease.